drugset / Trial / NCT06386302
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.
Timeline
- Start
- 2024-08-05
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |